Patents Represented by Attorney John S. Roberts
  • Patent number: 4552962
    Abstract: The present invention is concerned with dextrorotatory morphinans, which are illustrated by (+)-4-methoxy-6-keto-N-methylmorphinan. Related compounds which also have been introduced as cough-suppressing agents include the (+)-3-methoxy-N-methylmorphinans (ROMILAR-Roche).
    Type: Grant
    Filed: January 21, 1983
    Date of Patent: November 12, 1985
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventor: Arnold Brossi
  • Patent number: 4548218
    Abstract: A hair curler roller having a top and bottom end adapted to be heated while its bottom end is seated on one of a plurality of identical frusto-conical, heated posts of a heating unit. The roller consists of a cylindrical shell of a material of low heat conductivity, such as a synthetic resin, provided on its outside with hair-gripping means, and of a sleeve of a material of high conductivity, such as aluminum, inserted into the shell in intimate contact therewith. The top of the roller is preferably closed by suitable cover or cap of a synthetic resin, while the shell and the sleeve are open at their bottom. The sleeve comprises an upper cylindrical main portion closely adhering to the inside of the shell, and a lower, short neck portion of a smaller diameter, spaced apart from the shell wall. The neck portion is slotted by a plurality of slots permitting the outward expansion of the neck portion conforming to the shape of the frusto-conical post on which it is positioned.
    Type: Grant
    Filed: December 30, 1983
    Date of Patent: October 22, 1985
    Inventor: Dov Z. Glucksman
  • Patent number: 4547569
    Abstract: This invention discloses a molecule bearing a biologically active group (a phenanthridinium moiety) joined covalently to an oligonucleotide recognition system (a phosphorus nucleoside group) by a linker that permits intercalation of the active group in the pocket formed by the nucleotide and complementary bases in another polynucleotide strand. This class of compounds is illustrated by the following: ##STR1## where R is selected from the group consisting of --NH.sub.2, methylamino, or ethylamino or hydrogen;where R' is selected from the group consisting of --NH.sub.2, methylamino, or ethylamino or hydrogen;where the chain linking the linker group to the phenanthridinium group (R") consists of 2-8 --CH.sub.2 -- groups.
    Type: Grant
    Filed: June 14, 1984
    Date of Patent: October 15, 1985
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Robert L. Letsinger, Margaret E. Schott
  • Patent number: 4547367
    Abstract: Disclosed is a vaccine against hepatitis B virus (HBV) using purified hepatitis B core antigen (HBcAg). Chimpanzees immunized with the vaccine were protected against hepatitis B.
    Type: Grant
    Filed: December 20, 1983
    Date of Patent: October 15, 1985
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Edward Tabor, Robert J. Gerety
  • Patent number: 4547368
    Abstract: Disclosed is a a vaccine effective for primates, such as chimpanzees, and against hepatitis B virus (HBV) using hepatitis B core antigen (HBcAg) made by recombinant DNA. Chimpanzees immunized with the vaccine were protected against hepatitis B.
    Type: Grant
    Filed: August 6, 1984
    Date of Patent: October 15, 1985
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Edward Tabor, Robert J. Gerety
  • Patent number: 4545985
    Abstract: A method of modifying Pseudomonas exotoxin (PE) with methyl-4-mercaptobutyrimidate is disclosed so that after conjugating the exotoxin to a monoclonal antibody (ab) such as the antibody to the transferrin receptor, the PE-ab conjugate becomes a highly potent immunotoxin suitable for use against human tumor cells. This same method has been used to conjugate PE to epidermal growth factor (EGF) to create a highly potent growth factor-toxin conjugate for use against cells having large numbers of EGF receptors. Also disclosed are the immunotoxin conjugates for Pseudomonas exotoxin coupled to anti-TFR (antibody to the transferrin receptor) and anti-TAC (antibody to the human T-cell growth factor receptor) and to EGF.
    Type: Grant
    Filed: January 26, 1984
    Date of Patent: October 8, 1985
    Assignee: The United States of America as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Ira Pastan, Mark C. Willingham, David J. Fitzgerald
  • Patent number: 4533675
    Abstract: The present invention consists of derivatives of colchicine and thiocolchicine which are carbamates of the same and are illustrated by the formula below: ##STR1## where either X.sub.1 or X.sub.2 is a hydroxy group and the other a lower alkoxy group and R.sub.1 can be H or an alkyl, R.sub.2 an alkyl, alkenyl or aryl which may be substituted and R.sub.3 is either OCH.sub.3 or SCH.sub.3 ; alkyl and alkoxy=C.sub.1 -C.sub.6 ; aryl=monoaryl.These compounds are not only new but have exhibited antitumor activity binding to tubulin protein and tests against P388 lymphocytic leukemia and also active against gouty arthritis. Further, they are far less toxic than colchicine.
    Type: Grant
    Filed: April 17, 1984
    Date of Patent: August 6, 1985
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Arnold Brossi, Peter Kerekes
  • Patent number: 4532215
    Abstract: Human hepatitis A virus (HAV), taken directly from human clinical specimens, can be isolated and serially passaged in primary African green monkey kidney (AGMK) cell cultures. This strain induced antibody to HAV in inoculated chimpanzees and is useful for vaccine.
    Type: Grant
    Filed: April 7, 1982
    Date of Patent: July 30, 1985
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Richard J. Daemer, Stephen M. Feinstone, Ian D. Gust, Robert H. Purcell
  • Patent number: 4530735
    Abstract: This invention teaches the development of a chemical reagent useful as an aluminum brightening bath. The reagent's composition is primarily wet-process phosphoric acid to which has been added small quantities of nitric acid, copper, and optionally traces of several other substances. The reagent does not require expensive removal of the natural impurities found in wet-process phosphoric acid.
    Type: Grant
    Filed: September 28, 1982
    Date of Patent: July 23, 1985
    Assignees: Whitehurst Associates, Inc., Encee Chemical Sales, Inc.
    Inventors: Brooks M. Whitehurst, Donald F. Clemens, Taylor King, Garnett B. Whitehurst
  • Patent number: 4528196
    Abstract: The present invention consists of chelating agents for the treatment of iron overload and methods of using these agents in mammals such as mice and rats. These agents or compositions comprise diesters of dicarboxylic acids, which are phenolic derived and otherwise resemble ethylene and propylenediamine diacetic acids.The acids are known as: HBED [N,N'-bis(2-hydroxybenzyl)ethylenediamine N,N-diacetic acid]; EHPG [ethylenediamine N,N'-bis(2-hydroxyphenylacetic acid)]; HBPD [N,N'- bis(2-hydoxybenzyl)propylenediamine-N,N'-diacetic acid]; HBHPD [N,N'- bis(2-hydroxybenzyl)-2-hydroxy-1,3-propylenediamine-N,N'-diacetic acid].Mineral acid addition salts are also included in the spirit of this invention. Such salts as sulfuric, hydrochloric and nitric may be utilized.In activity it has been found that the odd-numbered carbon atom esters, such a dimethyl and dipentyl, specially of HBED, are of highest activity, as well as the dipentyl ester of the HBPD.
    Type: Grant
    Filed: February 23, 1981
    Date of Patent: July 9, 1985
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventor: Colin G. Pitt
  • Patent number: 4526288
    Abstract: A remotely controlled cover means for a storage bin or the like, comprised of a cover which may be opened from a remote location by means of a rope or the like attached to said cover and guidance means therefore. The pulling force exerted by the rope causes the cover to pivot up from the storage bin access opening, outwardly and downwardly by means of an offset angled pivot means. A spring latch device is employed to return the cover to the closed or spaced vented position when desired.
    Type: Grant
    Filed: August 24, 1982
    Date of Patent: July 2, 1985
    Inventor: Leo A. Schuld
  • Patent number: 4522918
    Abstract: Monoclonal antibodies demonstrating a reactivity with human breast cancer are produced. The hybridoma cultures secreting immunoglobins are produced by hydridoma technology. Splenic lymphocytes of mice, immunized with membrane-enriched fractions of metastatic human mammary carcinoma tissue are fused with the NS-1 non-immunoglobulin-secreting murine myeloma cell line. Screening of immunoglobulin reactivities and double cloning of cultures yielded 11 monoclonal antibodies that demonstrated activities with the surface of human mammary tumor cells and not with the surface of apparently normal human tissues. These monoclonal antibodies aid in the diagnosis, prognosis and treatment of human breast cancer.
    Type: Grant
    Filed: December 15, 1981
    Date of Patent: June 11, 1985
    Inventors: Jeffery Schlom, David Colcher, Marianna Nuti, Patricia H. Hand, Faye Austin
  • Patent number: 4521620
    Abstract: A method of producing acrylamide from acrylonitrile in the presence of a metallic conversion catalyst which comprises contacting an oil-in-water emulsion of acrylonitrile, said water phase being the continuous phase and containing up to 7% acrylonitrile and said oil phase being the dispersed phase and containing the remaining acrylonitrile to be converted to acrylamide, whereby a substantial portion of the acrylonitrile is converted to acrylamide which remains in the aqueous phase of the oil-in-water emulsion, and then an additional low HLB emulsifier is added to invert the oil-in-water emulsion to a water-in-oil emulsion containing acrylamide.
    Type: Grant
    Filed: December 9, 1981
    Date of Patent: June 4, 1985
    Assignee: Nalco Chemical Company
    Inventor: Kenneth G. Phillips
  • Patent number: 4521601
    Abstract: This invention relates to compounds which may be described as the unnatural enantiomers of morphine agonists and antagonists, which are useful as antitussives. The synthesis utilized is capable of producing all of the unnatural enantiomers of medically important opium derivatives of the morphinan type, including thebaine.
    Type: Grant
    Filed: March 23, 1983
    Date of Patent: June 4, 1985
    Assignee: The United States of America as represented by the Department of Health & Human Services
    Inventor: Kenner C. Rice
  • Patent number: 4520011
    Abstract: The rate of protein synthesis inhibition is significantly increased by adding excess ricin B chain to target cells independent of the amount of ricin A chain bound to the cell surface membrane. Ricin is a known toxin from albumin of the castor oil bean and contains an A chain and a B chain for binding to receptors. The present invention is concerned with ricin hybrids such as OX-7-ricin A chain and 19E12-F(ab) ricin A chain which were produced by conjugation of the ricin A chains with anti-Thy 1.1 monoclonal antibodies. The conjugates were utilized in pharmaceutical amounts in mice.
    Type: Grant
    Filed: February 19, 1982
    Date of Patent: May 28, 1985
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: David M. Neville, Jr., Richard J. Youle
  • Patent number: 4520113
    Abstract: This invention relates to the detection of antibodies in sera of AIDS and pre-AIDS patients and describes the biochemical and immunological analysis of antigens associated with the virus HTLV-III Human T-Cell Leukemia Virus. It is shown that antigens associated with the infection of human cells by this virus are specifically recognized by antibodies from AIDS patients. Specifically, HTLV-III isolated from AIDS patients and transmitted by cocultivation with an HT cell line is specifically detected by antibodies from human sera taken from AIDS patients. The method of detection of antibodies preferred is a strip radioimmunoassay (RIA) based on the Western Blot technique or an ELISA (an enzyme-linked immunosorbent assay) or an indirect immunofluorescence assay.
    Type: Grant
    Filed: April 23, 1984
    Date of Patent: May 28, 1985
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Robert C. Gallo, Mikulas Popovic, Mangalasseril G. Sarngadharan
  • Patent number: 4520031
    Abstract: A method of treating cancers or advanced malignant disease involving the weekly administration of methyl-glyoxal bis-guanylhydrazone in amounts of 250-1,000 mg/m.sup.2 per week. In particular the administration involves a weekly dosing regimen and dose escalation over the series of treatments from an initial dosage which may be 250 mg/m.sup.2.
    Type: Grant
    Filed: August 24, 1982
    Date of Patent: May 28, 1985
    Assignee: The United States of America as represented by the Secretary of Department of Health and Human Services
    Inventor: William A. Knight, III
  • Patent number: 4520226
    Abstract: A reagent and the protocol for the treatment of Graft Versus Host Disease is disclosed. Monoclonal antibodies specific for T-lymphocytes in human donor bone marrow are covalently linked to separate ricin toxin, combined in a mixture to form a treatment reagent, and combined with bone marrow removed from a human donor. The bone marrow-reagent mixture is then infused into an irradiated recipient. This protocol virtually eliminates T-lymphocyte activity, the cause of Graft Versus Host Disease.
    Type: Grant
    Filed: January 7, 1983
    Date of Patent: May 28, 1985
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: David M. Neville, Jr., Richard J. Youle
  • Patent number: 4512517
    Abstract: An irrigation sprinkler or water gun is retracted into an underground pit during non-irrigation periods, while the pit is closed by a heavy cover which is simultaneously lowered onto the pit opening. The sprinkler is mounted on a telescopic lifting unit which is connected to a point of an underground water supply system and is raised by water pressure as soon as this system is pressurized. The sprinkler communicates with the telescopic unit through a pressure relief valve which is opened by the water pressure only after the sprinkler has been raised to its highest point above ground. As soon as this valve opens water is admitted to the sprinkler which starts to rotate and to irrigate the area.
    Type: Grant
    Filed: August 31, 1982
    Date of Patent: April 23, 1985
    Inventor: Ron Manor
  • Patent number: 4511556
    Abstract: A method of inactivating a lipid virus in a protein carrier selected from the group consisting of Hepatitis B virus (HBV) and non-A, non-B hepatitis (NANBH) by contacting said virus for an extended period of time and ambient temperature with a halohydrocarbon treating agent preferably chloroform in an amount of 5% v/v to 50% v/v.
    Type: Grant
    Filed: June 10, 1982
    Date of Patent: April 16, 1985
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Robert H. Purcell, Stephen M. Feinstone